Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, 30 September 2026

It holds $503.4M more in cash and investments than it owes in debt. Shareholders’ equity is 97% of the balance sheet. What is a balance sheet?

30 September 2026 · total $514.5M

Owns

$628.0KLong-term assets
$10.3MOther short-term assets
$503.5MCash & all investments

Funded by

$497.6MShareholders’ equity
$16.7MOther liabilities
$100.0KDebt

Debt is 0.0% of the total; shareholders’ equity 96.7%.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
359.57 123.45 81.07 89.28
Total non-current assets
154.88 3.51 0.81 0.07
Total Assets
514.45 126.96 81.88 89.35
Total current liabilities
16.67 9.06 10.00 5.24
Total non-current liabilities
0.18 213.80 150.27 149.98
Total liabilities
16.85 222.86 160.27 155.22
Common Equity (Total)
497.60 (95.91) (78.39) (65.87)
Shareholders Equity (Total)
497.60 (95.91) (78.39) (65.87)
Total Debt
0.10 0.20 0.29 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026